SCHEMBL15034071

SCHEMBL15034071

COc1cc(C(=O)N2CCN(C(=O)c3ncn(-c4cccc(Cl)c4)n3)C(C)(C)C2)ccc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 2/20 0.43
TSHR P16473 2/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 5/20 0.41
POLB P06746 2/20 0.41
MGLL Q99685 2/20 0.41
SLC6A7 Q99884 1/20 0.40
HSD11B1 P28845 2/20 0.40
NPC1 O15118 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CFTR P13569 1/20 0.39
GAA P10253 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034095 0.91 ALDH1A1 (0.47) SMN1; SMN2ALDH1A1TSHRHTTNPSR1
SCHEMBL15034088 0.88 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1TSHRHTTNPSR1
SCHEMBL15019972 0.88 SLC6A7 (0.43) SMN1; SMN2ALDH1A1TSHRHTTNPSR1
SCHEMBL15034067 0.87 GRM5 (0.47) ALDH1A1MGLLHPGD
SCHEMBL15034089 0.87 MGLL (0.46) SMN1; SMN2ALDH1A1TSHRHTTNPSR1
SCHEMBL15034054 0.86 SLC6A7 (0.43) SMN1; SMN2ALDH1A1TSHRHTTNPSR1
SCHEMBL15034215 0.85 HPGD (0.43) SMN1; SMN2ALDH1A1TSHRHTTNPSR1
SCHEMBL15034094 0.85 SLC6A7 (0.42) SMN1; SMN2ALDH1A1TSHRHTTNPSR1
SCHEMBL15034093 0.85 WNK1 (0.47) ALDH1A1MGLLSLC6A7CFTRHPGD
SCHEMBL15034052 0.85 TSHR (0.43) SMN1; SMN2ALDH1A1TSHRHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 SMN1; SMN2 2592/4885ALDH1A1 3952/4885TSHR 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.